Head-To-Head Survey: JATT Acquisition (NYSE:JATT) Versus Novavax (NASDAQ:NVAX)
Head-To-Head Survey: JATT Acquisition (NYSE:JATT) Versus Novavax (NASDAQ:NVAX)
JATT Acquisition (NYSE:JATT – Get Rating) and Novavax (NASDAQ:NVAX – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.
JATT Acquisition（紐約證券交易所代碼：JATT — 獲取評級）和 Novavax（納斯達克股票代碼：NVAX — 獲取評級）都是小型醫療公司，但哪家業務更好？我們將根據兩家公司的股息、估值、分析師建議、機構所有權、風險、盈利能力和收益對比這兩家公司。
Institutional & Insider Ownership
機構和內部所有權
44.8% of JATT Acquisition shares are owned by institutional investors. Comparatively, 42.6% of Novavax shares are owned by institutional investors. 2.1% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
JATT Acquision的44.8％的股份由機構投資者擁有。相比之下，Novavax有42.6％的股票由機構投資者持有。2.1％的Novavax股票由公司內部人士擁有。強大的機構所有權表明捐贈基金、大型基金經理和對沖基金認爲股票有望實現長期增長。
Profitability
盈利能力
This table compares JATT Acquisition and Novavax's net margins, return on equity and return on assets.
該表比較了JATT Acquisition和Novavax的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| JATT Acquisition | N/A | -105.35% | 6.64% |
| Novavax | -114.32% | -572.54% | -55.69% |
| 淨利潤 | 股本回報率 | 資產回報率 | |
| 收購 JATT | 不適用 | -105.35% | 6.64% |
| Novavax | -114.32% | -572.54% | -55.69% |
Earnings & Valuation
收益與估值
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| JATT Acquisition | N/A | N/A | $6.85 million | N/A | N/A |
| Novavax | $1.15 billion | 1.43 | -$1.74 billion | ($19.46) | -1.08 |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股收益 | 市盈率 | |
| 收購 JATT | 不適用 | 不適用 | 685 萬美元 | 不適用 | 不適用 |
| Novavax | 11.5 億美元 | 1.43 | -17.4 億美元 | （19.46 美元） | -1.08 |
JATT Acquisition has higher earnings, but lower revenue than Novavax.
JATT Acquisition的收益更高，但收入低於Novavax。
Analyst Ratings
分析師評級
This is a summary of current ratings for JATT Acquisition and Novavax, as reported by MarketBeat.com.
這是Marketbeat.com報道的JATT Accusition和Novavax當前評級的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| JATT Acquisition | 0 | 0 | 0 | 0 | N/A |
| Novavax | 2 | 0 | 5 | 0 | 2.43 |
| 賣出評級 | 持有評級 | 買入評級 | 強勁的買入評級 | 評分分數 | |
| 收購 JATT | 0 | 0 | 0 | 0 | 不適用 |
| Novavax | 2 | 0 | 5 | 0 | 2.43 |
Novavax has a consensus price target of $128.25, indicating a potential upside of 510.71%. Given Novavax's higher possible upside, analysts plainly believe Novavax is more favorable than JATT Acquisition.
Novavax的共識目標股價爲128.25美元，表明潛在的上漲空間爲510.71％。鑑於Novavax可能有更高的上行空間，分析師顯然認爲Novavax比JATT收購更有利。
Summary
摘要
JATT Acquisition beats Novavax on 5 of the 9 factors compared between the two stocks.
JATT Accusition在兩隻股票的9個因素中有5個擊敗了Novavax。
About JATT Acquisition
關於收購 JATT
(Get Rating)
（獲取評級）
JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.
JATT 收購公司沒有重大業務。它打算與一個或多個企業或實體進行合併、資本股份交換、資產收購、股份購買、重組或類似的業務合併。該公司打算專注於主要在生命科學領域運營的業務。JATT Acquisition Corp 於 2021 年成立，總部位於開曼羣島的大開曼島。
About Novavax
關於 Novavax
(Get Rating)
（獲取評級）
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax, Inc. 是一家生物技術公司，專注於疫苗的發現、開發和商業化，以預防嚴重傳染病和滿足健康需求。該公司的候選疫苗包括NVx-CoV2373，這是一種正在進行兩項III期試驗、一項IIb期試驗和一項I/II期試驗的冠狀病毒候選疫苗；nanoFlu，一種正在進行三期臨床試驗的納米顆粒季節性四價流感候選疫苗；以及呼吸道合胞病毒 (RSV) 融合 (F) 蛋白納米顆粒候選疫苗ResVax。它還在開發RSV F疫苗，該疫苗已進入針對老年人（60歲及以上）的II期臨床試驗，也正在爲兒科進行I期臨床試驗。它與武田製藥有限公司簽訂了合作協議，用於開發、製造和商業化 COVID-19 候選疫苗 nvx-coV2373。Novavax, Inc. 成立於 1987 年，總部位於馬里蘭州蓋瑟斯堡。
Receive News & Ratings for JATT Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JATT Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收收購 JATT 的新聞和評級 -在下面輸入您的電子郵件地址，即可通過Marketbeat.com的免費每日電子郵件時事通訊接收JATT Accuction及相關公司的最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。